The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
Open accessAbstract
Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin-dependent diabetes mellitus (NIDDM).Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion.We sought to determine the role of  cell function in mediating improved glucose tolerance.Obese subjects with IGT received 12 wk of either 400 mg daily of troglitazone ( n ϭ 14) or placebo ( n ϭ 7) in a randomized, double-blind design.Study measures at baseline and after treatment were glucose and insulin responses to a 75-g oral glucose tolerance test, insulin sensitivity index (S I ) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion rates during a graded glucose infusion, and  cell glucose-sensing ability during an oscillatory glucose infusion.Troglitazone reduced integrated glucose and insulin responses to oral glucose by 10% ( P ϭ 0.03) and 39% ( P ϭ 0.003), respectively.S I increased from 1.3 Ϯ 0.3 to 2.6 Ϯ 0.4 ϫ 10 Ϫ 5 min Ϫ 1 pM Ϫ 1 ( P ϭ 0.005).Average insulin secretion rates adjusted for S I over the glucose interval 5-11 mmol/liter were increased by 52% ( P ϭ 0.02), and the ability of the  cell to entrain to an exogenous oscillatory glucose infusion, as evaluated by analysis of spectral power, was improved by 49% ( P ϭ 0.04).No significant changes in these parameters were demonstrated in the placebo group.In addition to increasing insulin sensitivity, we demonstrate that troglitazone improves the reduced  cell response to glucose characteristic of subjects with IGT.This appears to be an important factor in the observed improvement in glucose tolerance.( J. Clin.Invest.1997.100: 530-537.)Key words: thiazoles • insulin resistance • insulin secretion • non-insulin-dependent diabetes mellitus • glucose intolerance Methods SubjectsThe study design was that of a double blind, placebo-controlled clinical trial in which two subjects were assigned to treatment with troglitazone for every one subject treated with placebo.Randomization was performed by Parke-Davis Pharmaceutical Research Division, Warner Lambert Co. (Ann Arbor, MI), who kindly provided the study medication and placebo.The groups were well matched for age, degree of obesity, and extent of glucose intolerance (for all compari-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the concept of a feedback loop, it has become evident that subjects who are at high risk of developing Type 2 diabetes have diminished beta-cell function at a time when many of them still have NGT.”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,990
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,645
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,197
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Bergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
Physical activity and reduced occurrence of non–insulin-dependent diabetes mellitus
Helmrich, S. P., Ragland, D. R., Leung, R. W., & Paffenbarger, R. S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250302 · Cited by 1,634
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–216 of 216
Prevention of Type 2 and Gestational Diabetes
Hamman, R. F., & Dabelea, D. (2010) · Wiley eBooks · doi:10.1002/9780470682807.ch5
Dynamic Controversies of Pioglitazone
Laway, B. A., & Kotwal, S. K. (2012) · International Journal of Medicine and Public Health · doi:10.4103/2230-8598.108381
Genetically defined pancreatic beta cell failure
Smit, J. W. A., & Diamant, M. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.5.669
Metabolic disorders associated with the evolution to type 2 diabetes mellitus in a risk group
Suárez, R. M. G., Amador, P., & Calzado, C. M. A. (2010) · Revista cubana de endocrinología
Az inzulinrezisztencia farmakológiai befolyásolhatóságának lehetőségei
Kovács, D. K. (2015) · University of Debrecen Electronic Archive (University of Debrecen)
Zhang, B., Shiomi, M., Tanaka, H., Mei, J., Fan, P., Tsujita, Y., Horikoshi, H., & Saku, K. (2001) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190395
Thomas-Geevarghese, A., & Herold, K. C. (2004)
Shalaby, A. A., & Boshra, V. (2008) · Mansoura Medical Journal · doi:10.21608/mjmu.2008.128912
Methodologies of Pharmacodynamic Assessment
Pfeiffer, C., & Ruus, P. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_28
Ben‐Ezra, V. (2005) · CRC Press eBooks · doi:10.1201/9781420038422.ch8
Thomas-Geevarghese, A., & Herold, K. C. (2004) · Springer eBooks · doi:10.1007/978-1-4757-6260-0_40
Wu, Y., Wang, Z., Tuersun, A., Yu, Q., Zhong, Y., Ali, S. S. A., Liu, H., Hu, X., Zhang, Y., Pang, L., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04705-2
Nath, R., Das, L., Chakraborty, A., Maiti, N. J., Bhattacharjee, S., Maity, A., Khan, S. A., Al-Ghazali, M. A., Debnath, B., & Akhtar, M. J. (2026) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2026.2714227
Metadata
- Authors
- Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- ORCID
- Byrne, M M
- Venue
- Journal of Clinical Investigation
- Published
- 1997-08-01
- Volume
- 100
- Issue
- 3
- Pages
- 530-537
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508219
- OpenAlex
- W2085390992
- Cited by
- 216
- References
- 63
- Citations by year
- 2026: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 2 · 2012: 5
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- troglitazone, impaired glucose tolerance, beta-cell function, insulin secretion, insulin sensitivity, insulin resistance, type 2 diabetes, glucose tolerance, thiazolidinediones, oral glucose tolerance test, insulin sensitivity index, insulin secretion rate, type 2 diabetes prevention, insulin sensitizers
- MeSH terms
- Troglitazone, Administration, Oral, Adult, Animals, Chromans, Double-Blind Method, Female, Glucose, Glucose Tolerance Test, Guinea Pigs, Humans, Hypoglycemic Agents, Islets of Langerhans, Male, Middle Aged, Thiazoles, Treatment Outcome, Glucose Intolerance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
